SCHEMBL30765760

SCHEMBL30765760

COC(=O)C(C)n1c(-c2ccccc2F)ncc(N[C@H](C)c2ccc3oc4ccccc4c3c2)c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRB1 P18505 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36
GABRA4 P48169 1/20 0.36
GABRE P78334 1/20 0.36
GABRA6 Q16445 1/20 0.36
GABRG1 Q8N1C3 1/20 0.36
GABRG3 Q99928 1/20 0.36
GABRQ Q9UN88 1/20 0.36
P2RX3 P56373 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765669 0.93 KIT (0.35) CYP1A2CYP2C9CYP2C19GABRPGABRD
SCHEMBL30765837 0.93 KIT (0.35) CYP1A2CYP2C9CYP2C19GABRPGABRD
SCHEMBL30766151 0.84 ELANE (0.37) CYP2C9GABRPGABRDGABRA1GABRB1
SCHEMBL30765559 0.83 P2RX3 (0.36) CYP1A2CYP2C9CYP2C19GABRPGABRD
SCHEMBL30765981 0.79 LMNA (0.37) CYP1A2CYP2C9CYP2C19ALDH1A1HPGD
SCHEMBL31558470 0.79 LMNA (0.37) CYP1A2CYP2C9CYP2C19ALDH1A1HPGD
SCHEMBL30765525 0.78 CYP1A2 (0.38) CYP1A2CYP2C9CYP2C19ALOX5ALDH1A1
SCHEMBL30765454 0.77 ELANE (0.37) CYP1A2CYP2C9CYP2C19KITDDR2
SCHEMBL30765701 0.77 ALDH1A1 (0.35) CYP1A2CYP2C9CYP2C19ALDH1A1HPGD
SCHEMBL30765756 0.76 GABRP (0.41) CYP1A2CYP2C9CYP2C19GABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed